All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @onebadmuvaluva on TikTok · 13s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @onebadmuvaluva's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Make me all I want for this month
  2. 0:05It is you
  3. 0:06Yeah, yeah, yeah
  4. 0:09Slits in the face, I like
  5. 0:10Like, I like it, I like it
  6. 0:12Yeah, yeah, yeah, yeah

Wegovy before-and-after videos: what the weight loss data actually shows

Nurse_Shaunie

TikTok creator

76.8K viewsWatch on TikTok

Quick answer

This video presents a personal visual testimonial attributed to Wegovy (semaglutide 2.4 mg), a GLP-1 receptor agonist FDA-approved for chronic weight management in adults with obesity or overweight with comorbidities. The creator offers no verbal medical claims, but the before-and-after format implies predictable, replicable weight loss results. Clinical evidence supports meaningful average weight loss with semaglutide, but individual results, side effect burden, and weight regain upon discontinuation are not represented in this format.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Wegovy before-and-after videos: what the weight loss data actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Wegovy before-and-after videos: what the weight loss data actually shows" from Nurse_Shaunie. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: This video presents a personal visual testimonial attributed to Wegovy (semaglutide 2.

The reason this review is not generic is the source wording and the canonical claim label "glp1 had to run this one back wegovy before and after one belly o." In this clip, the useful excerpt is: "Make me all I want for this month It is you Yeah, yeah, yeah Slits in the face, I like Like, I like it, I like it Yeah, yeah, yeah, yeah" That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

STEP 4 trial (Rubino et al.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

This video presents a personal visual testimonial attributed to Wegovy (semaglutide 2.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • This video presents a personal visual testimonial attributed to Wegovy (semaglutide 2.4 mg), a GLP-1 receptor agonist FDA-approved for chronic weight management in adults with obesity or overweight with comorbidities. The creator offers no verbal medical claims, but the before-and-after format implies predictable, replicable weight loss results. Clinical evidence supports meaningful average weight loss with semaglutide, but individual results, side effect burden, and weight regain upon discontinuation are not represented in this format.
  • STEP 1 trial (Wilding et al., 2021, NEJM): adults on semaglutide 2.4 mg lost an average of 14.9% body weight over 68 weeks, versus 2.4% on placebo.
  • STEP 4 trial (Rubino et al., 2021, JAMA): participants who stopped semaglutide regained about two-thirds of lost weight within 12 months, meaning this is likely a long-term medication, not a course.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • STEP 1 trial (Wilding et al., 2021, NEJM): adults on semaglutide 2.4 mg lost an average of 14.9% body weight over 68 weeks, versus 2.4% on placebo.
  • STEP 4 trial (Rubino et al., 2021, JAMA): participants who stopped semaglutide regained about two-thirds of lost weight within 12 months, meaning this is likely a long-term medication, not a course.
  • Roughly 44% of participants in STEP trials reported nausea; gastrointestinal side effects were the leading cause of treatment discontinuation.
  • Wegovy is FDA-approved for BMI 30 or above, or BMI 27 or above with at least one weight-related comorbidity. It is not approved for cosmetic weight loss.
  • Compounded semaglutide is not FDA-approved and is not equivalent to brand-name Wegovy in terms of regulated potency, purity, or safety testing.
  • Before-and-after images cannot show variables like dose, duration, diet, exercise, or side effects, all of which significantly affect outcomes.
  • Individual results in clinical trials varied widely around the 14.9% average, meaning some patients lost far less and a subset did not respond meaningfully.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @onebadmuvaluva actually say?

Honestly, not much. The transcript from this video is mostly song lyrics and filler sounds, not any medical claims. The real communication here is visual: a before-and-after body transformation attributed to Wegovy, paired with a caption joking about losing "one belly, one back, one neck." That is the claim being made, and it is being made through images and humor rather than words.

The creator identifies as a nurse in their hashtags, which adds an implicit layer of credibility. Viewers are likely reading this as: Wegovy did this, it works, look at the results. Whether or not that was the intent, that is the message landing with 76,800 people. Visual testimonials work exactly like verbal ones in terms of audience influence, and they deserve the same scrutiny.

Does the science back this up?

The general premise, that semaglutide (Wegovy) produces meaningful weight loss, is well-supported. The question is what a single before-and-after photo actually tells you about that evidence, and the answer is: very little.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) followed 1,961 adults over 68 weeks and found that participants on 2.4 mg semaglutide lost an average of 14.9% of body weight versus 2.4% on placebo. That is a real, clinically significant effect. The STEP 4 trial (Rubino et al., 2021, JAMA) added an important wrinkle: people who stopped taking the drug regained two-thirds of their lost weight within a year. Neither of those data points shows up in a before-and-after photo.

What also does not show up: how long the creator has been on the medication, what dose, what their diet looked like, whether they exercise, or whether that "after" photo will still represent them in 12 months. Before-and-after images strip out every variable that actually determines whether a result is replicable.

What did they get wrong (or right)?

To be fair, the creator did not make any false medical claims. They did not say Wegovy is safe for everyone, did not quote a dose, did not promise anyone else would get the same result. The video is more of a personal celebration than a medical recommendation, and that context matters.

What is missing is any acknowledgment of what Wegovy actually requires: a prescription, medical supervision, ongoing use, and a realistic understanding of side effects. The STEP trials reported that roughly 44% of participants experienced nausea, and gastrointestinal side effects were the most common reason people discontinued treatment (Wilding et al., 2021). None of that makes it into a caption about losing a neck.

The implicit message, which is hard to separate from the visual, is that Wegovy is a straightforward solution with dramatic results. That framing leaves out the hard parts. It is not dishonest, but it is incomplete in ways that could lead viewers to underestimate what they are signing up for.

What should you actually know?

Semaglutide is one of the most studied weight-loss drugs currently available, and the evidence for it is genuinely strong. But a few things are worth keeping in your head before a TikTok transformation video sends you to an online pharmacy.

  • Weight loss on Wegovy is real but not guaranteed to match what you see in any individual's photos. Results in the STEP trials varied significantly across participants.
  • The drug works while you take it. Rubino et al. (2021, JAMA) showed substantial weight regain after stopping, which means this is likely a long-term commitment, not a one-time fix.
  • Side effects are common, not rare. Nausea, vomiting, constipation, and diarrhea affect a large portion of users, particularly early in treatment.
  • Wegovy is FDA-approved for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. It is not a lifestyle drug for people with a few pounds to lose.
  • Compounded semaglutide is not the same as Wegovy. FDA has been explicit that compounded versions are not FDA-approved and may vary in potency and purity.

Before-and-after content on social media is not peer review. It is one person's experience, filtered through camera angles and captions. That experience may be completely real and still tell you almost nothing about what yours would look like.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Nurse_Shaunie · TikTok creator

76.8K views on this video

Had to run this one back. Wegovy before and after. One belly, one back, one neck. 😭 #CapCut #fypシ #weightloss #weightlossjourney #wegovy #xyzbca #foryoupage #nursesoftiktok

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about step 1 trial (wilding et al., 2021, nejm): adults on?

STEP 1 trial (Wilding et al., 2021, NEJM): adults on semaglutide 2.4 mg lost an average of 14.9% body weight over 68 weeks, versus 2.4% on placebo.

What does the video say about step 4 trial (rubino et al., 2021, jama): participants who?

STEP 4 trial (Rubino et al., 2021, JAMA): participants who stopped semaglutide regained about two-thirds of lost weight within 12 months, meaning this is likely a long-term medication, not a course.

What does the video say about roughly 44% of participants in step trials reported nausea; gastrointestinal?

Roughly 44% of participants in STEP trials reported nausea; gastrointestinal side effects were the leading cause of treatment discontinuation.

What does the video say about wegovy?

Wegovy is FDA-approved for BMI 30 or above, or BMI 27 or above with at least one weight-related comorbidity. It is not approved for cosmetic weight loss.

What does the video say about compounded semaglutide?

Compounded semaglutide is not FDA-approved and is not equivalent to brand-name Wegovy in terms of regulated potency, purity, or safety testing.

What does the video say about before-and-after images cannot show variables like dose, duration, diet, exercise,?

Before-and-after images cannot show variables like dose, duration, diet, exercise, or side effects, all of which significantly affect outcomes.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Nurse_Shaunie, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.